Ricardo Ramos, MD
Cardiovascular Disease · Saint Joseph, MONPI 1568574770
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,340 of the $5,353 with a category attached, or 81.1%. It is spread thinly across 23 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,755, 2.4 times the $731 reported in 2019.
Across 193 payments — averaging $27.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biosense Webster, Inc.$1K
- Abbott$1K
- Biotronik Inc.$714
- Boston Scientific$493
- Medtronic$445
- Pfizer$277
- plus $1K from 17 others
Across 1 payment — averaging $13,578 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$14K
What the payments were for
- Travel & lodging$1,01319%
- Food & beverage$4,34081%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biosense Webster, Inc. | 30 | $1,151 |
| Abbott | 21 | $1,002 |
| Biotronik Inc. | 12 | $714 |
| Boston Scientific | 25 | $493 |
| Medtronic(2 entities) | 13 | $445 |
| Pfizer | 19 | $277 |
| Amgen | 15 | $225 |
| Sanofi-aventis U.S. LLC | 14 | $206 |
| Heartflow, Inc. | 6 | $202 |
| Johnson & Johnson | 8 | $139 |
| AstraZeneca | 8 | $112 |
| Novartis | 7 | $102 |
| Altathera Pharmaceuticals LLC | 1 | $42 |
| Daiichi Sankyo Inc. | 2 | $41 |
| Boehringer Ingelheim | 2 | $37 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $36 |
| AbbVie | 1 | $27 |
| E.r. Squibb & Sons, L.L.C. | 2 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Chiesi USA, Inc. | 1 | $16 |
| Impulse Dynamics (USA) Inc. | 1 | $15 |
| Braemar Manufacturing, LLC | 1 | $14 |
| Philips North America LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$589
- Solia$359
- Selectra$359
- Carto 3$287
- AURORA EV-ICD MRI SURESCAN$153
- Confidense$114
- Micra$104
How this compares
$5,353 in reported general payments places this provider in the 70th percentile of 391 cardiovascular disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 301 | $303,171 |
| XareltoRivaroxaban | 147 | $177,974 |
| EntrestoSacubitril/Valsartan | 55 | $63,645 |
| JardianceEmpagliflozin | 32 | $38,268 |
| Repatha SureclickEvolocumab | 14 | $17,679 |
| BrilintaTicagrelor | 24 | $10,464 |
| Dofetilide | 28 | $8,869 |
| Metoprolol Succinate | 379 | $5,315 |
| Rosuvastatin Calcium | 320 | $4,431 |
| VascepaIcosapent Ethyl | 11 | $4,165 |
| Potassium Chloride | 222 | $3,515 |
| Atorvastatin Calcium | 429 | $3,237 |
| Carvedilol | 387 | $2,887 |
| Metoprolol Tartrate | 440 | $2,857 |
| Amiodarone Hcl | 253 | $2,781 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $277 | $303,171301 claims |
| Johnson & JohnsonXarelto | $139 | $177,974147 claims |
| NovartisEntresto | $102 | $63,64555 claims |
| Boehringer IngelheimJardiance | $37 | $38,26832 claims |
| AstraZenecaBrilinta | $112 | $10,46424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 391 cardiovascular disease providers in Missouri.
Other cardiovascular disease in Saint Joseph
- Mohan HindupurSaint Joseph$28K
- German KamalovSaint Joseph$20K
- Mikhail KosiborodKansas City$1.1M
- Georges ChahoudSaint Louis$937K
- William BowenSaint Louis$726K
- Daniel KellySaint Louis$582K
- John SpertusKansas City$360K
- James FairlambColumbia$342K
- James EllisonChesterfield$267K
- Osler Jay GuzonSaint Louis$211K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.